Crispr Therapeutics AG vs Cenovus Energy Inc — how do they compare? Crispr Therapeutics AG trades at $53.84 (market cap $5.23B), while Cenovus Energy Inc trades at $30.25 (market cap $55.00B). The key difference: Cenovus Energy Inc is far larger — about 10.5× Crispr Therapeutics AG's market cap, and Cenovus Energy Inc pays a 2.09% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | CVE | |
|---|---|---|
Market Cap | $5.23B | $55.00B |
Sector | Health | Energy |
52-Week High | $76.78 | $31.80 |
52-Week Low | $44.34 | $14.83 |
Enterprise Value | $3.65B | $61.08B |
Dividend Yield | — | 2.09% |
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Cenovus Energy (CVE) trades at $30.2, up 2.17% today, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, matching estimates with $1.11 EPS, and raised full-year production guidance. Valuation ratios appear attractive with a P/E of 11.56 and EV/EBITDA of 5.77, while profitability remains solid with an 11.48% net income margin and 20.96% ROE.
Outlook is positive driven by higher oil prices and record oil sands production, but risks include commodity price volatility and refining margin pressures. Analyst consensus leans bullish with 11 Buy ratings, though geopolitical tensions and Canadian regulations pose headwinds for sustained growth.
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →